Mýliti se je lidské …
Klíčová slova:
ONC201, patentová ochrana, klinické hodnocení, záměna isomerů, analytická kontrolaAbstrakt
The compound originally known as TIC10 or ONC201 is a new anticancer drug developed by Oncoceutics, Inc. The agent's Investigational New Drug Application for phase I/II clinical studies has been recently approved by Food & Drug Administration. However, a Scripp Institute's group revealed that the compound structure given in all documents, including patents, was erroneous and applied for a patent protection for the correct structure. Chemistry backgrounds associated with this case is reviewed together with the relevant consequences regarding the intellectual property issue.
Stahování
Publikováno
15.01.2015
Jak citovat
Rádl, S. (2015). Mýliti se je lidské …. Chemické Listy, 109(1), 3–6. Získáno z http://blog.chemicke-listy.cz/ojs3/index.php/chemicke-listy/article/view/406
Číslo
Sekce
Články
